Posts

Posted on

TV Sales Volume of TCL Electronics in 2020 Reached 23.93 Million, Overshoots Its Sales Target and Hits a New High

TV Sales Volume of TCL Electronics in 2020 Reached 23.93 Million, Overshoots Its Sales Target and Hits a New High

Sales Volume in 2020 up 15.9% YoY

Sales in Overseas Markets Increase 27.2% YoY

HONG KONG–(BUSINESS WIRE)–TCL Electronics Holdings Limited (“TCL Electronics” or “the Company“, HKSE stock code: 01070.HK) announced that its sales volumes of TCL brand TV in the fourth quarter of 2020 (from October to December) increased by 20.2% year on year to 6.61 million sets. The sales volumes in the whole year of 2020 (from January to December) reached 23.93 million sets with a year-on-year growth of 15.9%, overshooting its sales target and hitting a new high.

In spite of COVID-19 pandemic in 2020, the Company leveraged its globally deployed production capacity and advantages in vertical integration for the industry chain to seize sales opportunities as markets rebounded. The sales volume of TCL brand TVs in 2020 kept strong growth momentum. Meanwhile, the Company kept enhancing its product competitiveness and brand power and improving its product mix. The sales volume of its smart TVs and 4K TVs increased by 24.1% and 26.3% year-on-year, respectively. The proportions of smart TVs and 4K TVs increased by 6.0 percentage points and 4.5 percentage points year-on-year, which accounted for 91.3% and 55.6% of the overall sales volume, respectively. With a year-on-year growth of 2.8 percentage points, the proportion of Quantum Dot TVs, which were mostly sold to overseas markets, reached 3.4%. With best-in-class Mini LED backlight technology, the Company was the first in the industry to achieve mass production for Mini LED TVs, and its sales volume of Mini LED TVs led the pack.

In overseas markets, the annual sales volume of TCL brand TV of the Company reached 17.13 million sets, up by 27.2% year-on-year and recorded strong sales growth in most regional markets. In North America, its annual sales volume rose by 25.4% year-on-year. In Europe, sales volume in 2020 rose 66.0% year-on-year. Especially, sales volume of France, Italy and Nordic notably increased by 20.7%, 24.2% and 85.6%, respectively. In the emerging markets, the Company further expanded its distribution channels and sales volume in 2020 surged by 19.4%. Specifically, sales volume in Japan, Brazil, Australia, Indonesia and Russia notably increased by 181.3%, 67.9%, 45.9%, 40.8% and 31.4%, respectively.

Sales in the PRC market continued on a streak of growth in the fourth quarter in 2020, which witnessed a year-on-year growth of 7.5% and a quarter-on-quarter growth of 34.4%. The sales volume in 2020 slightly declined to 6.8 million sets, which was mainly due to the shut-down of most offline stores in February and March last year because of COVID-19 pandemic, creating a slack season during the first quarter. Smart TVs and 4K TVs accounted for 92.0% and 63.7% of the fourth quarter’s sales volume and 89.8% and 64.2% of the sales volume in 2020, up by 6.9 percentage points year-on-year and 4.3 percentage points year-on-year, respectively. The Company kept optimizing its product mix and channel structure in the PRC market to further enhance stronger competitiveness.

Smart mobile and connective device business was consolidated for the first time in September 2020.The sales volume of smart mobile and connective device from September to December of 2020 reached 11.7 million sets, up by 14.1% year-on-year compared with the same period of 2019.

In 2020, the Company further expanded the user base for its Internet business. As of 31 Dec 2020, the number of monthly active users reached 17.91 million, up by 15.5% year-on-year.

TCL Electronics is committed to developing the smart display industry and striving to serve global users. Its global market share keep rising over the past three years. In the first three quarters of 2020, the Company ranked among global top 3 in terms of sales volume of branded TVs. As a Chinese leading player in the smart display industry, the Company made concerted efforts to fight against COVID-19 pandemic and successfully overshot its sales target in 2020. In 2021, it will further ramp up R&D and product innovation, focusing on AI as well as advanced display technologies like Mini LED, 8K, and Quantum Dot. Meanwhile, it keeps broadening its global market share and thereby consolidate its leading position. In addition, as continuing focuses on Internet business, the Company will insist on its “AI x IoT” strategy to become a world-leading smart technology company and create more value for its shareholders.

The whole year of 2020 and the fourth quarter of 2020 (Unaudited)

 

January to

December

2020

  

January to

December

2019

  

Y-o-Y

Change

(%)

   

October to

December

2020

  

October to

December

2019

 

Y-o-Y

Change

(%)

 

TCL Brand TV sales

volume

23,927,464

 

 

20,641,617

 

 

15.9

%

  

6,606,898

 

 

5,495,654

 

 

20.2

%

 

 

 

 

 

 

   

 

 

 

 

 

 

－　PRC Market

(TCL Brand)

6,799,548

 

 

7,179,202

 

 

-5.3

%

  

2,312,870

 

 

2,151,303

 

 

7.5

%

－　Overseas Markets

(TCL Brand)

17,127,916

 

 

13,462,415

 

 

27.2

%

  

4,294,028

 

 

3,344,351

 

 

28.4

%

 

 

 

 

 

 

   

 

 

 

 

 

 

Proportion of TCL Brand

Smart TV (%)

91.3

%

  

85.3

%

  

+6.0p.p.

    

93.4

%

  

86.5

%

 

+6.9p.p.

  

Proportion of TCL Brand

4K TV (%)

55.6

%

  

51.1

%

  

+4.5p.p.

    

59.6

%

  

57.0

%

 

+2.6p.p.

  

About TCL Electronics

Headquartered in Shenzhen, China, TCL Electronics Holdings Limited (stock code: 01070.HK, incorporated in the Cayman Islands with limited liability) is engaged in the research and development, manufacturing and distribution of consumer electronic products such as smart TVs and mobile communication devices and independently developed home Internet services. TCL Electronics has emerged as a world-leading and China’s only diversified consumer electronics platform with advantages of vertically integrated industrial chain. With smart display as the core of the strategy and 5G and “AI x IoT” as technology drivers, TCL Electronics provides users with a smart and healthy life with household, mobile and commercial scenarios and is devoted to becoming a world-leading smart technology company. According to the latest report from Sigmaintell, the market share of global brand smart TV of TCL Electronics in the third quarter of 2020 ranked Top 3 in the world. With leading positions in the domestic and overseas markets, the MAU and ARPU of TCL Electronics’ home Internet operation platform (“Falcon Network Technology”) both ranked among the top in the PRC market. TCL Electronics has also emerged as the industry’s only Chinese company with sustainable and large-scale revenue in the overseas Internet services. TCL Electronics is included in the eligible shares list of the Shenzhen-Hong Kong Stock Connect Scheme, Hang Seng Stock Connect Hong Kong Index, Hang Seng Composite MidCap & SmallCap Index and Hang Seng Corporate Sustainability Benchmark Index. For more information, please visit the website of investor relations of TCL Electronics: http://electronics.tcl.com.

For Enquiries:

TCL Electronics

Mr. Terence Ng Tel: 852-2437 7481

Email：[email protected]

Hong Kong Zhixin Financial News Agency Limited

Ms. Rachel Lei Tel: (86-755) 8254 5361

Ms. Lilian Lam Tel: (86-755) 8255 0643

Ms. Jules Zhu Tel: (86-755) 8277 0579

Ms. Fancy Wang Tel: (86-755) 2589 3557

Mr. Jason Wang Tel: (86-755) 2394 1306

Email:[email protected]

KEYWORDS: Asia Pacific Hong Kong

INDUSTRY KEYWORDS: Consumer Electronics Technology Telecommunications Mobile/Wireless Software Networks Internet

MEDIA:

Logo
Logo
Posted on

iQIYI Expands Its International Footprint, Announcing Its Animation, Deer Squad Airing on Nickelodeon in the US on January 25, 2021

PR Newswire

BEIJING, Jan. 14, 2021 /PRNewswire/ — iQIYI, Inc. (NASDAQ: IQ) (“iQIYI” or the “Company”), an innovative market-leading online entertainment service in China, announced today that its original CG-animated series in collaboration with Nickelodeon International and VIS Kids, a division of ViacomCBS International Studios, Deer Squad, will premiere on Nickelodeon in the U.S. on January 25th, 2021. The airing of Deer Squad in the US market is a testament to the high quality of this iQIYI original animation and marks the successful entry of Chinese animation into an international market.

An adventure-rescue animation, Deer Squad tells the story of four lovable, enthusiastic and heroic deer friends Kai, Lola, Rammy and Bobbi, who protect the animals of Central Forest and the humans who inhabit Platinum City, a futuristic metropolis surrounding their woodland home. When there’s trouble, the Deer summon their Planet Powers and transform into a team that can solve problems using their Planet Powers of Water (Kai), Wood (Lola), Earth (Bobbi) and Sun (Rammy). The animation series premiered on iQIYI on July 15, 2020 and was the most played show on the Chinese internet for seven consecutive weeks among all animations aired in the past four months.

Nickelodeon International aired Deer Squad across Asia in August 2020, including on iQIYI’s platform in China. The show premiered in Australia, New Zealand and the UK later in the year. It was the #1 show in the Philippines amongst kids 2-141, ranked Nick Jr. as the #1 STV channel in Australia among kids 0-4 during Deer Squad premieres2 and averaged +148% in the UK compared to the timeslot benchmark3. It is scheduled to air in Europe and Africa in March 2021.

Created with a global audience in mind, Deer Squad is a successful attempt for iQIYI to enter the international animation market with its own animation IP. iQIYI initiated the cooperation with the Nickelodeon International and ViacomCBS International Studio (VIS) Kids teams, collaborating throughout the entire production process and providing crucial feedback to help bridge the cultural gap between Chinese and international audiences. This innovative in-depth collaboration model has provided new avenues and possibilities for domestic animation to travel beyond its own shores.

In terms of production values, Deer Squad was benchmarked against the highest  international standard in order to perfect the show’s screenplay, character design, animation effects and other aspects, which will be key to its success in the competitive international market.

Yang Xiaoxuan, Vice President of iQIYI and Head of Original Animation and Investment said, “Deer Squad is a major breakthrough for iQIYI’s development of original children’s animation, creatively supervised by Nickelodeon. We appreciate Nickelodeon’s international broadcasting strategy on the show, and it is great news that we have achieved No.1 in viewership in many regions. We hope that there will be more Chinese original animations to go international.”  

“We first partnered with iQIYI on the series with a worldwide audience in mind. We’re incredibly proud to see this original pre-school series become the first global Chinese-originated collaborative project as we further our commitment to developing kids-first content from around the world,” said Nina Hahn, Senior Vice President of International Production & Development for Nickelodeon International and Head of VIS Kids.

iQIYI has been expanding its global resources and partnerships in the children’s animation space in recent years, working with renowned animation houses to provide premium content. In the future, iQIYI will deliver on its commitment of creating high-quality and original IPs and look to further expand its IP industry chain by hosting events and developing spin-offs and merchandise. These initiatives will allow the Company to realize the full commercial value of its IPs while simultaneously enhancing the children’s content industry and boosting the international competitiveness of Chinese-made original animation.


About iQIYI, Inc.

iQIYI, Inc. is an innovative market-leading online entertainment service in China. Its corporate DNA combines creative talent with technology, fostering an environment for continuous innovation and the production of blockbuster content. iQIYI’s platform features highly popular original content, as well as a comprehensive library of other professionally-produced content, partner-generated content and user generated content. The Company distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. iQIYI attracts a massive user base with tremendous user engagement and has developed a diversified monetization model including membership services, online advertising services, content distribution, live broadcasting, online games, IP licensing, online literature and e-commerce.


About Nickelodeon International

Nickelodeon, now in its 41st year, is the number-one entertainment brand for kids. It has built a diverse, global business by putting kids first in everything it does. The brand includes television programming and production in the United States and around the world, plus consumer products, digital, location-based experiences, publishing and feature films. Nickelodeon is one of the most globally recognized and widely distributed multimedia entertainment brands for kids and family, available in nearly 400 million households across 170+ countries and territories, via more than 80+ locally programmed channels and branded blocks. Outside of the United States, Nickelodeon is part of ViacomCBS Networks International, a division of ViacomCBS Inc. (Nasdaq: VIACA, VIAC). For more information or artwork, visit http://www.nickpress.com. Nickelodeon and all related titles, characters and logos are trademarks of ViacomCBS Inc. 


About ViacomCBS International Studios (VIS)

Introduced in 2018, ViacomCBS International Studios (VIS) is a division of ViacomCBS Networks International that produces content for ViacomCBS brands and platforms, including Paramount+, Nickelodeon, MTV, Comedy Central, Channel 5, Network 10, Telefe and Porta Dos Fundos, as well as for third parties. In 2020, VIS Kids launched to further the expansion of the studio’s global kids content pipeline. The content that VIS produces covers all genres, from pre-school to young adult and across live action and animation, as well as soap operas, dramas, short and long-form comedy formats and feature film productions. VIS global sales include original productions, co-productions, formats sold for local adaptations, and sale of ready-made content.


1 Kids 2-14s in the premiered weekdays (3rd Aug – 14th Aug 2020, @1600-1629). Source: Kantar Media, TechEdge, Nickelodeon PHL, 0600-2159, Period Run 3rd Aug – 14th Aug


2 Kids 0-4 in the premiered weekdays (12th October – 23rd October 2020, @1630-1659). Source: Nielsen, TechEdge, Nick Jr AU, 0600-1959


3 Kids 4-15 in the premiered weekdays (1st October – 16th October 2020, @0730-0759). Source: BARB, TechEdge, Nick Jr UK, Total Day

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/iqiyi-expands-its-international-footprint-announcing-its-animation-deer-squad-airing-on-nickelodeon-in-the-us-on-january-25-2021-301208114.html

SOURCE iQIYI

Posted on

Pure Extracts Delineates Study on Psilocybin Oral Tablets, Capsules and Nasal Gel

VANCOUVER, British Columbia, Jan. 14, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has delineated the timetable and milestones for its study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. The study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to the Company.

The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms that could be used in future efficacy clinical trials by both Pure Extracts and its pharmaceutical customers. Clinical batch manufacturing, packaging and labelling are all included in the study as is conformity testing and stability testing (including both long-term and accelerated). The study will conform to both Canadian Good Manufacturing Practice (“GMP”) and Good Clinical Practice (“GCP”) standards.

The key milestones in the 250-day timeline for the study on psilocybin immediate release tablets and nasal gel include the following:

  • Sourcing and procurement of medicinal ingredients, excipients & packaging materials
  • Raw Material Testing
  • Formulation and Manufacturing Process Development, Stability Testing
  • Clinical Batch Manufacturing
  • Quality Control Release Testing
  • Shipping of Clinical Batches to CRO

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited about the R&D progress we are going to make with TIPT over the next 6 – 8 months while waiting to receive our Dealer’s License from Health Canada. We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms.”


About Pure Extracts

(CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD

“

Ben Nikolaevsky

”

Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. The Company is in the preliminary stages of preparing a Dealer’s License application and there is no certainty on the timing of such application, or that the Company will ultimately be successful in obtaining a Dealer’s License. Submission of the Company’s Dealer’s License application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.



Posted on

IBM Helps Audi UK Reimagine the Digital Customer Experience

Online sales inquiries increase 59%; car buying experience puts prospective customers in the driver’s seat

PR Newswire

ARMONK, N.Y. and LONDON, Jan. 14, 2021 /PRNewswire/ — IBM [NYSE: IBM] and Audi UK, one of the world’s leading premium automotive manufacturers, collaborated to redesign Audi’s website to deliver a far more engaging digital customer experience. During the course of 2020, Audi has seen a 59% increase in UK online sales inquiries despite an almost 30% industry decline in new UK car sales during the pandemic.

 

With 90% of its car purchases starting online, Audi UK turned to IBM iX, the business design arm of IBM Global Business Services, to help it reimagine its customers’ digital journey from initial inquiry to ownership. COVID-19 has made “contact-less” online experience paramount as car dealerships had to close or limit in-person operations.

Audi UK’s digital transformation unified its mobile and desktop shopping experiences, enabled by a cloud platform and supported by the latest marketing insights data from Adobe Analytics and agile software development practices.

Audi UK tailors the customers’ online experience to their prime motivations for car-buying – be it price, driving experience, technology or safety. Visitors are now asked fewer questions, can reach relevant information more quickly and are offered more contact options to take their inquiry further than they could before.  Audi UK broke its own online sales inquiries record three times in June 2020 alone.

Antony Roberts, Head of Digital at Audi UK, says: “In a matter of 12 months, our leads have grown exponentially and our sales conversions have improved. We have gone from being poor in terms of the data analytics to being incredibly rich. Through our collaboration with IBM, Audi UK now has the most effective cloud-based online platform across the entire VW Group, building a smarter experience for customers interacting with our brand.”

Like most organizations, Audi’s IT architecture was built over many years and had become challenging to maintain. Applying the agile, user-focused IBM Garage Methodology, the Audi and IBM iX team co-created a strategic roadmap for their digital transformation, resulting in new customer-centric tools designed to enhance the user experience. IBM implemented Adobe Experience Manager along with Adobe Analytics to facilitate faster content-led experiences on their website that helped enable Audi to make business and customer-experience decisions based on data rather than assumptions, with a full view into how consumers interact with the new site:

  • IBM built the Audi analytics platform using Adobe Analytics which has helped provide actionable marketing insights, and pinpoints site performance improvement opportunities, resulting in Audi reducing customer submission errors by 90%.
  • Audi content editors are now able to complete everyday changes themselves, freeing developers to focus on more complex tasks. Audi has created libraries of reusable components that has reduced initial setup time of new features from weeks to minutes.
  • Adopting more agile practices, developers are now able to deliver functionality up to 75% faster than before; new solutions built this year include a test-drive booking application, a vehicle maintenance scheduler and a part-exchange calculator.

Debbie Vavangas, IBM Global Garage lead, IBM iX, said: “Audi has prided itself on its commitment to apply smart design across its business. With the COVID-19 pandemic up-ending the way consumers make large purchases, there was a critical need to apply its design principles to its customers’ digital experiences. By embracing cloud technologies and data analytics, Audi UK helped accelerate its digital transformation with an online platform that delivers a smarter, more engaging experience that puts customers in the driver’s seat.”

Notes to editors

The Society of Motor Manufacturers and Traders (SMMT) announces, in its UK January 2021 report, a 29% fall in new car registrations in 2020: https://www.smmt.co.uk/2021/01/uk-automotive-looks-to-green-recovery-strategy-after-29-4-fall-in-new-car-registrations-in-2020/

The 59% increase quoted above represents the growth in fully qualified sales inquiries generated on www.audi.co.uk during 2020 over the previous year, which were passed to Audi sales or its business partners.

About Audi UK
Headquartered in Milton Keynes, England, Audi UK, a premium automotive manufacturer, operates 115 Audi Centres in the UK. Founded in 1885, Audi currently serves approximately 2 million customers and employs more than 90,000 people globally. Approximately 175,000 customers and 10,000 employees are based in the UK. Audi UK operates under parent company Volkswagen Group.

About IBM
For further information about IBM iX services visit: https://www.ibm.com/services/ibmix/ 
For further information about the IBM Garage visit: https://www.ibm.com/garage

Media Contacts

Marisa Conway

IBM External Relations
[email protected]

John Galvez

IBM UK External Relations
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ibm-helps-audi-uk-reimagine-the-digital-customer-experience-301208062.html

SOURCE IBM

Posted on

Nano Dimension Prices $332.5 Million Registered Direct Offering

Sunrise, Florida, Jan. 13, 2021 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM), a leading Additively Manufactured Electronics (AME)/PE (Printed Electronics) provider, today announced it has entered into definitive agreements with investors for the sale of 35,000,000 of the Company’s American Depositary Shares (“ADSs”) at a price of $9.50 per ADS pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $332.5 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds for working capital and for other general corporate purposes, and pursuing strategic opportunities, including possible business combination transactions. The closing of the registered direct offering is expected to take place on or about January 19, 2021, subject to the satisfaction of customary closing conditions.

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-251155) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, Telephone: (877) 436-3673; Email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nano Dimension

Nano Dimension (Nasdaq: NNDM) is a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). High fidelity active electronic and electromechanical subassemblies are integral enablers of autonomous intelligent drones, cars, satellites, smartphones, and in vivo medical devices. They necessitate iterative development, IP safety, fast time-to-market and device performance gains, thereby mandating AME for in-house, rapid prototyping and production. Nano Dimension machines serve cross-industry needs by depositing proprietary consumable conductive and dielectric materials simultaneously, while concurrently integrating in-situ capacitors, antennas, coils, transformers and electromechanical components, to function at unprecedented performance. Nano Dimension bridges the gap between printed circuit board and semiconductor integrated circuits. A revolution at the click of a button: From computer-aided design (CAD) to a functional high-performance AME device in hours, solely at the cost of the consumable materials. 

For more information, please visit www.nano-di.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nano Dimension is using forward-looking statements in this press release when it discusses expected timing of the closing of the offering and planned use of the net proceeds from the offering. Because such statements deal with future events and are based on Nano Dimension’s current expectations, they are subject to various risks and uncertainties. Actual results, performance or achievements of Nano Dimension could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Nano Dimension’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Nano Dimension is not responsible for the contents of third-party websites.

NANO DIMENSION INVESTOR RELATIONS CONTACT

Yael Sandler, CFO | [email protected]



Posted on

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

OSAKA, Japan–(BUSINESS WIRE)–
NIPPON SHOKUBAI CO., LTD. (TOKYO:4114) (https://www.shokubai.co.jp/en/) has decided to begin facility design of new electrolytes “IONELTM – Lithium bis(fluorosulfonyl) imide [LiFSI]” for lithium-ion batteries by setting up the “IONEL Construction Team” on October 1, 2020 in order to construct new manufacturing facilities (annual production capacity: 2,000 tons; location: Ichikawa, Chiba) using its own process. The decision is made because current production capacity, the annual production capacity of 300 ton, is insufficient for the increasing demand. Commercial production by the new facility will start from spring 2023.

IONELhas an excellent effect in improving the life, the charge/discharge rate performance, and the durability at low/high temperatures for the batteries. With this excellent effect, Our Producthas been enjoying high reputation in the industries.

To meet our customers’ demand, in addition to efforts to improve the performance of Our Product, we have been making efforts to protect Our Product by means of applying for and securing a number of patents, including 44 patents listed below.

We respectfully request all persons who look at this notice to pay utmost attention not to infringe our patents in purchasing, selling or using products which make use of our patents of other companies that are unrelated to NIPPON SHOKUBAI.

We are dedicated to continue to make efforts for further improvement and development of Our Product with better technologies. We would sincerely appreciate your continued patronage for Our Product.

Patent No.

US9079780

(Alkali Metal Salt of Fluorosulfonyl Imide, and Production Method Thereof)

US9586833

(Alkali Metal Salt of Fluorosulfonyl Imide, and Production Method Thereof)

US9985317

(Alkali Metal Salt of Fluorosulfonyl Imide, and Production Method Thereof)

NIPPON SHOKUBAI Announcement

https://www.shokubai.co.jp/en/news/news0256.html

New Energy Materials Sales ＆ Marketing Dept.

Energy ＆ Electronics Solutions Div.

NIPPON SHOKUBAI CO., LTD.

Keiichiro Mizuta

TEL: +81-6-6223-9197

Kogin Bldg., 4-1-1 Koraibashi, Chuo-ku, Osaka 541-0043

[email protected]

KEYWORDS: United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Other Manufacturing Alternative Vehicles/Fuels Technology Automotive Chemicals/Plastics Other Technology Automotive Manufacturing Alternative Energy Manufacturing Energy

MEDIA:

Logo
Logo
Posted on

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

OSAKA, Japan–(BUSINESS WIRE)–
NIPPON SHOKUBAI CO., LTD. (TOKYO:4114) (https://www.shokubai.co.jp/en/) has decided to begin facility design of new electrolytes “IONELTM – Lithium bis(fluorosulfonyl) imide [LiFSI]” for lithium-ion batteries by setting up the “IONEL Construction Team” on October 1, 2020 in order to construct new manufacturing facilities (annual production capacity: 2,000 tons; location: Ichikawa, Chiba) using its own process. The decision is made because current production capacity, the annual production capacity of 300 ton, is insufficient for the increasing demand. Commercial production by the new facility will start from spring 2023.

IONELhas an excellent effect in improving the life, the charge/discharge rate performance, and the durability at low/high temperatures for the batteries. With this excellent effect, Our Producthas been enjoying high reputation in the industries.

To meet our customers’ demand, in addition to efforts to improve the performance of Our Product, we have been making efforts to protect Our Product by means of applying for and securing a number of patents, including 44 patents listed below.

We respectfully request all persons who look at this notice to pay utmost attention not to infringe our patents in purchasing, selling or using products which make use of our patents of other companies that are unrelated to NIPPON SHOKUBAI.

We are dedicated to continue to make efforts for further improvement and development of Our Product with better technologies. We would sincerely appreciate your continued patronage for Our Product.

Patent No.

EP 2 257 495 B1

SULFONYLlMIDE SALT AND METHOD FOR PRODUCING THE SAME currently in force in CH, FR.

EP 2 578 533 B1

ALKALI METAL SALT OF FLUOROSULFONYL IMIDE, AND PRODUCTION METHOD THEREFOR currently in force in CZ, DE, FR, HU, PL, SE

NIPPON SHOKUBAI Announcement

https://www.shokubai.co.jp/en/news/news0256.html

New Energy Materials Sales ＆ Marketing Dept.

Energy ＆ Electronics Solutions Div.

NIPPON SHOKUBAI CO., LTD.

Keiichiro Mizuta

TEL: +81-6-6223-9197

Kogin Bldg., 4-1-1 Koraibashi, Chuo-ku, Osaka 541-0043

[email protected]

KEYWORDS: Europe Japan Asia Pacific

INDUSTRY KEYWORDS: Other Manufacturing Alternative Vehicles/Fuels Technology Automotive Chemicals/Plastics Other Technology Automotive Manufacturing Alternative Energy Manufacturing Energy

MEDIA:

Logo
Logo
Posted on

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

OSAKA, Japan–(BUSINESS WIRE)–
NIPPON SHOKUBAI CO., LTD. (TOKYO:4114) (https://www.shokubai.co.jp/en/) has decided to begin facility design of new electrolytes “IONEL®, – Lithium bis(fluorosulfonyl) imide [LiFSI]” for lithium-ion batteries by setting up the “IONEL Construction Team” on October 1, 2020 in order to construct new manufacturing facilities (annual production capacity: 2,000 tons; location: Ichikawa, Chiba) using its own process. The decision is made because current production capacity, the annual production capacity of 300 ton, is insufficient for the increasing demand. Commercial production by the new facility will start from spring 2023.

IONELhas an excellent effect in improving the life, the charge/discharge rate performance, and the durability at low/high temperatures for the batteries. With this excellent effect, Our Producthas been enjoying high reputation in the industries.

To meet our customers’ demand, in addition to efforts to improve the performance of Our Product, we have been making efforts to protect Our Product by means of applying for and securing a number of patents, including 44 patents listed below.

We respectfully request all persons who look at this notice to pay utmost attention not to infringe our patents in purchasing, selling or using products which make use of our patents of other companies that are unrelated to NIPPON SHOKUBAI.

We are dedicated to continue to make efforts for further improvement and development of Our Product with better technologies. We would sincerely appreciate your continued patronage for Our Product.

Patent No.

CN ZL200980111233.6

SULFONYLlMIDE SALT AND METHOD FOR PRODUCING THE SAME

CN ZL201180026278.0

ALKALI METAL SALT OF FLUOROSULFONYL IMIDE, AND PRODUCTION METHOD THEREFOR

CN ZL201480008985.0

ELECTROLYTE SOLUTION AND LITHIUM ION SECONDARY BATTERY PROVIDED WITH SAME

 

NIPPON SHOKUBAI Announcement

https://www.shokubai.co.jp/cn/news/

NISSHOKU TRADING (SHANGHAI) CO., LTD

Pei Xia

TEL: +86-21-5407-5959

R/No.3604,The Center,989 Changle Road, Shanghai 200031, China

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Other Manufacturing Alternative Vehicles/Fuels Technology Automotive Chemicals/Plastics Other Technology Automotive Manufacturing Alternative Energy Manufacturing Energy

MEDIA:

Logo
Logo
Posted on

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

NIPPON SHOKUBAI: Enhancement of Facilities and Patent Rights for Lithium-ion Battery Electrolyte IONEL (LiFSI)

OSAKA, Japan–(BUSINESS WIRE)–
NIPPON SHOKUBAI CO., LTD. (TOKYO:4114) (https://www.shokubai.co.jp/en/) has decided to begin facility design of new electrolytes “IONEL® – Lithium bis(fluorosulfonyl) imide [LiFSI]” for lithium-ion batteries by setting up the “IONEL Construction Team” on October 1, 2020 in order to construct new manufacturing facilities (annual production capacity: 2,000 tons; location: Ichikawa, Chiba) using its own process. The decision is made because current production capacity, the annual production capacity of 300 ton, is insufficient for the increasing demand. Commercial production by the new facility will start from spring 2023.

IONELhas an excellent effect in improving the life, the charge/discharge rate performance, and the durability at low/high temperatures for the batteries. With this excellent effect, Our Producthas been enjoying high reputation in the industries.

To meet our customers’ demand, in addition to efforts to improve the performance of Our Product, we have been making efforts to protect Our Product by means of applying for and securing a number of patents, including 44 patents listed below.

We respectfully request all persons who look at this notice to pay utmost attention not to infringe our patents in purchasing, selling or using products which make use of our patents of other companies that are unrelated to NIPPON SHOKUBAI.

We are dedicated to continue to make efforts for further improvement and development of Our Product with better technologies. We would sincerely appreciate your continued patronage for Our Product.

Patent No.

KR1345271 　

FLUOROSULFONYL IMIDE SALT AND METHOD FOR PRODUCING　FLUOROSULFONYL IMIDE SALT

KR1361701 　

ALKALI METAL SALT OF FLUOROSULFONYL IMIDE, AND PRODUCTION METHOD THEREFOR

KR2141903　

ELECTROLYTE SOLUTION AND LITHIUM ION SECONDARY BATTERY PROVIDED WITH SAME

 

NIPPON SHOKUBAI Announcement

https://korean.shokubai.co.jp/news/

NIPPON SHOKUBAI CO., LTD.

Nippon Shokubai Korea Co., Ltd.

Joon-Hyung Park

TEL: 82-2-704-9113

12F Dowon Bldg.,34, Mapo-daero, Mapo-gu, Seoul, 04174, Korea

KEYWORDS: South Korea Japan Asia Pacific

INDUSTRY KEYWORDS: Other Manufacturing Alternative Vehicles/Fuels Technology Automotive Chemicals/Plastics Other Technology Automotive Manufacturing Alternative Energy Manufacturing Energy

MEDIA:

Logo
Logo
Posted on

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC). This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

“This approval for tislelizumab is an important milestone for BeiGene, for tislelizumab, and for the patients and healthcare practitioners in China fighting advanced squamous NSCLC,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. “This is our sixth global approval for an internally-developed product, and our first approval for tislelizumab in a lung cancer indication, an area where we believe tislelizumab can have a large impact for patients.”

“With the recent announcement that the RATIONALE 303 trial met its primary endpoint of overall survival at its interim analysis, three Phase 3 trials of tislelizumab in NSCLC have achieved a positive outcome at interim analysis,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “Tislelizumab is being investigated in a broad clinical program, including five Phase 3 trials in lung cancer indications. We believe that it is an important immunotherapy and demonstrates our work at BeiGene to bring innovative, impactful, and quality treatments to patients in need.”

“Lung cancer is the leading cause of cancer-related death in China, and with NSCLC comprising the most common form of the disease, there is significant patient need. We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer,” said Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. “In its Phase 3 trial in this indication, tislelizumab, combined with standard chemotherapy demonstrated a clinically meaningful benefit as assessed by progression-free survival and response rates.”

“The approval of tislelizumab for patients with advanced squamous NSCLC was made possible by the courageous patients who participated in the trial, the dedicated clinicians who helped conduct the trial, and our hard-working team at BeiGene. We are humbled by the expeditious review of our supplemental new drug application and hope our broad development program for tislelizumab will continue its momentum and benefit additional patients,” said Wendy Yan, Senior Vice President and Global Head of Regulatory Affairs at BeiGene.

The approval of tislelizumab for the treatment of patients with advanced squamous NSCLC was supported by clinical results from a Phase 3 trial of tislelizumab combined with either paclitaxel and carboplatin or nab-paclitaxel (ABRAXANE®) and carboplatin compared to paclitaxel and carboplatin alone in patients with untreated stage IIIB or IV squamous NSCLC from mainland China (NCT03594747). A total of 360 patients were randomized 1:1:1 to receive tislelizumab in combination with either chemotherapy regimen or chemotherapy alone. As announced in January 2020, the trial met the primary endpoint of statistically significant improvement in progression-free survival (PFS), as assessed by independent review committee (IRC), in the pre-planned interim analysis. The safety profile of tislelizumab in both combinations was consistent with the known risks of each study treatment, and no new safety signals were identified. The results of the interim analysis of the trial were presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

About Non-Small Cell Lung Cancer

In contrast to most Western countries, where lung cancer death rates are decreasing, the lung cancer incidence rate is still increasing in China.i,ii There were approximately 815,563 new cases of lung cancer in China in 2020 and it is the leading cause of cancer-related death in both men and women, with approximately 714,699 deaths in China in 2020.iii Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 80 to 85 percent of all case.iv

About Tislelizumab

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.v Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. Tislelizumab has also received conditional approval from the NMPA for the treatment of patients with classical Hodgkin’s lymphoma who received at least two prior therapies and for the treatment of patients with locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Complete approval for these indications is contingent upon results from ongoing randomized, controlled confirmatory clinical trials.

In addition, two supplemental new drug applications for tislelizumab have been accepted by the Center for Drug Evaluation (CDE) of the NMPA and are under review for first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and for previously treated unresectable hepatocellular carcinoma.

Currently, 15 potentially registration-enabling clinical trials are being conducted in China and globally, including 13 Phase 3 trials and two pivotal Phase 2 trials.

Tislelizumab is not approved for use outside of China.

About Tislelizumab Clinical Program

Clinical trials of tislelizumab include:

  • Phase 3 trial comparing tislelizumab to salvage chemotherapy in patients with relapsed/refractory classical Hodgkin Lymphoma (NCT04486391);
  • Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977);
  • Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with NSCLC (NCT03358875);
  • Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747);
  • Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205);
  • Phase 3 trial of tislelizumab in combination with platinum-based doublet chemotherapy as neoadjuvant treatment for patients with NSCLC (NCT04379635);
  • Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716);
  • Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC; NCT03412773);
  • Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897);
  • Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC; NCT03430843);
  • Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442);
  • Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590);
  • Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657);
  • Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889); and
  • Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986).

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s further advancement of, and anticipated clinical development, regulatory milestones and commercialization of tislelizumab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

ABRAXANE® is a registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company.

i Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

ii She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions. Chest 2013;143:1117-26.

iii The Global Cancer Observatory. Available at https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed December 2020.

iv American Cancer Society. Available at https://www.cancer.org/cancer/lung-cancer/about/what-is.html#:~:text=About%2080%25%20to%2085%25%20of,(outlook)%20are%20often%20similar. Accessed December 2020.

v Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., Shi, Y., Bai, H., Liu, N., Yang, X., Cui, X., Cao, Y., Liu, Q., Song, J., Li, Y., Tang, Z., … Li, K. (2018). The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer immunology, immunotherapy : CII, 67(7), 1079–1090. https://doi.org/10.1007/s00262-018-2160-x

Investor Contact

Craig West

+1 857-302-5189

[email protected]

Media Contact

Liza Heapes or Vivian Ni

+1 857-302-5663 or + 1 857-302-7596

[email protected]

KEYWORDS: Massachusetts China United States North America Asia Pacific

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo